Bluejay Therapeutics, a company specializing in the development of drugs for the treatment of severe viral infections and liver diseases, is considering an Initial Public Offering (IPO) on U.S. stock markets. This initiative could represent a significant milestone for the company and increase its capitalization, but it also carries risks due to the current market conditions.